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Abstract
Background: Painful infectious mouth conditions are a common presentation to emergency departments.
Although self limiting, painful ulcerative lesions and inflamed mucosa can decrease oral intake and can lead to
dehydration. Oral analgesia is of limited efficacy and is often refused by the patient. Despite widespread use of oral
2% viscous lidocaine for many years, there is little evidence for its efficacy as an analgesic and in aiding oral intake
in children with painful infectious mouth conditions. This study aims to establish the effectiveness of 2% viscous
lidocaine in increasing oral intake in these children by comparing it with placebo.
Methods/Design: This study is a randomised double-blind placebo controlled trial of children between 6 months
and 8 years of age with painful infectious mouth conditions defined as gingivostomatitis (herpetic or non
herpetic), ulcerative pharyngitis, herpangina and hand foot and mouth disease as assessed by the treating clinician
in association with a history of poor oral fluid intake. It will be conducted at a single tertiary paediatric emergency
department in Melbourne Australia.
20 patients have already been randomised to receive 2% lidocaine or placebo in a pilot study to determine the
sample size in a preplanned adaptive design. A further 80 patients will be randomised to receive either 2%
lidocaine or placebo. The placebo agent is identical to lidocaine in terms of appearance, flavour and smell. All
clinical and research staff involved, patients and their parents will be blinded to treatment allocation.
The primary endpoint is the amount of fluid ingested by each child, expressed in ml/kg, within 60 minutes from the
time of administration of the study mixture. Secondary endpoints are the proportion of patients ingesting 5 ml/kg and
10 ml/kg at 30 and 60 minutes after drug administration and the incidence of adverse events. Longer term outcomes
will include the proportion of patients requiring hospital admission and length of emergency department stay.
Discussion: This trial will define the role of 2% lidocaine in the treatment of painful infectious mouth conditions
Trial registration: The trial is registered with the Australian and New Zealand Clinical Trials Registry -
ACTRN12609000566235.
Background
Painful infectious mouth conditions are a common pre-
sentation to paediatric emergency departments. These
are usually viral conditionss u c ha sg i n g i v o s t o m a t i t i s
(herpetic and non herpetic), ulcerative pharyngitis,
herpangina and hand foot and mouth disease. Most of
the paediatric literature concerns primary herpetic gingi-
vostomatitis (PHGS) caused by infection with the herpes
simplex virus. Although self limiting, there is consider-
able morbidity from decreased oral intake. Amir et al
found that 89% of patients with PHGS drank less than
normal [1]. The oral lesions can persist for 7 to 18 days
with the risk of dehydration [2]. The presence of extra-
oral lesions in addition to intra-oral lesions is highly
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any medium, provided the original work is properly cited.indicative of PHGS [3], and may be used to differentiate
PHGS from other ulcerative mouth conditions of chil-
dren: mainly herpangina and hand foot and mouth dis-
ease (both caused by the coxsackie virus). In
herpangina, lesions are typically seen on the posterior
portion of the oral cavity and palate, with an absence of
extra-oral lesions. Hand foot and mouth disease typically
has both intra-oral and extra-oral lesions and the distri-
bution of characteristic lesions on the hands and feet
distinguishes it from PHGS [4]. These findings are parti-
cularly valuable as the majority of PHGS cases are diag-
nosed on clinical findings alone. Treatment for such
conditions is generally symptomatic and therefore a pre-
cise diagnosis is not critical as such.
The mainstay of care for children with gingivostomati-
tis is supportive and expectant. The primary goal of
therapy in acute care is directed towards pain relief
from ulcerative lesions and inflamed mucosa, thus facili-
tating oral fluid intake to prevent dehydration. Often,
routine oral analgesia is the first mode of therapy
attempted by parents at home. However, it may have lit-
tle effect in the relief of pain and is often refused by the
patient. If oral intake cannot be improved, there is a
subsequent risk of admission to hospital for intravenous
(IV) or nasogastric (NG) fluids. Amir et al [3] found
that 3 out of 36 (8%) children presenting with herpes
gingivostomatitis experienced dehydration and required
hospitalisation for IV rehydration.
Treatment trials for painful infectious mouth condi-
tions have focussed on the efficacy of acyclovir and
similar antiviral agents for treating PHGS with contro-
versy about the strength and weakness of the evidence
of its efficacy [2,5,6]. Regardless, acyclovir use is of lim-
ited relevance where acute fluid intake of a child in the
ED is concerned and the exact diagnosis is often not
known. Many agents have been described for painful
ulcerative mouth conditions in adults and children
including gingivostomatitis, oral candidiasis and
aphthous ulcers. Agents used for one or a number of
conditions include viscous lidocaine, benzocaine pre-
parations, diphenhydramine elixir, coating agents includ-
ing Maalox, milk of magnesia and Kaopectate,
antibiotics particularly chlorhexidine and tetracycline
and topical steroids [7-21]. In a retrospective chart
review of 48 non immune suppressed paediatric patients
presenting with PHGS at the Children’s Hospital in Buf-
falo, United States[2], all were treated with analgesics
such as acetaminophen or ibuprofen, 35 were treated
with a mixture of Maalox and diphenhydramine, 8 with
acyclovir, 7 with viscous lidocaine and 11 received two
or more of these therapies. A major textbook of Paedia-
tric Emergency Medicine [10] mentions rinsing with vis-
cous lidocaine, as well as “magic mouthwash” (a mixture
of Kaopectate and Benadryl) as treatment options. 2%
viscous lidocaine has been recommended in the study
hospital ED Clinical Practice Guidelines (CPG) for the
treatment of herpes gingivostomatitis for many years
[9]. To date, however, there have been no RCTs investi-
gating any topical anaesthetic for painful ulcerative con-
ditions of the mouth in previously health children.
There are some data from adult ulcerative mouth con-
ditions and patients with cancer related mucositis. In a
double blind RCT Saxen et al [11] randomised 60 adults
with aphthous ulcers to one of 3 treatment groups - 3%
diclofenac in 2.5% hyaluronan, 2.5% hyaluronan or 3%
viscous lidocaine. For spontaneous and stimulated pain
a significant reduction in pain was shown in all 3 groups
(p < 0.01) with no demonstrable difference between the
3 topical agents. Akhionbare and Ojehanon [12] rando-
mised 30 patients with aphthous ulcers to either 2%
plain lidocaine or 2% lidocaine with adrenaline. 87% of
patients experienced a complete relief of pain after
application of either solution. Although different etiolo-
gically, oral mucositis often results in unrelenting pain
causing an inability to eat and drink with subsequent
risk of malnutrition and dehydration. In this respect it is
similar to severe infectious mouth conditions. Yet, a
review of the literature on the management of mucositis
demonstrates a lack of consensus of scientific opinion
on optimal treatment for relieving painful mucositis [22]
and the use of a large variety of different topical agents
including diphenhydramine, viscous lidocaine, magne-
sium hydroxide and aluminium hydroxide (Maalox),
nystatin and corticosteroids has been described [23].
RCT data are limited and a Cochrane review [24] found
that there was “no proven and satisfactory treatment
available” for oral mucositis in the adult population.
Similarly, a paediatric review [22] revealed a paucity of
controlled trials in children, highlighting that current
practice is governed more by clinical experience rather
than scientific evidence.
Lidocaine, the first amide-type local anesthetic, is
commonly used topically for a number of indications. A
flavoured 2% solution of lidocaine hydrochloride (2%
viscous lidocaine, trade name Xylocaine Viscous
® Astra
Zeneca) is commercially available. Local anaesthesia is
achieved within approximately 5 minutes and the dura-
tion of anaesthesia lasts between 20 and 30 minutes
[25]. The recommended maximum dose of lignocaine is
3 mg/kg, 3 hourly, which equals 0.15 ml/kg of 2% vis-
cous lidocaine. Adverse events from topical lidocaine
administration are uncommon and have only been
reported when used beyond the recommended doses
[26,27].
Ulcerative lesions and inflamed mucosa due to viral
infections in children are frequent reasons for presenta-
tions and can be associated with decreased oral intake
and the risk of dehydration. Despite their widespread
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topical agents, in particular topical lidocaine for painful
infectious mouth conditions in otherwise healthy chil-
dren. We set out to assess if 2% viscous lidocaine can
increase oral intake in these children by comparing it
with placebo.
Methods/Design
Study Aims
The primary research question of this study is whether
topical 2% viscous lidocaine is effective in improving the
poor oral intake associated with painful infectious
mouth conditions compared to placebo in children
within 60 minutes of administration.
Study Design and Setting
This study is a randomised double-blind placebo con-
trolled trial. It will be conducted at a single tertiary pae-
diatric emergency department (ED) in the Royal
Children’s Hospital (RCH), Melbourne, Australia.
Ethical Considerations
The study has ethical approval at the study hospital. All par-
ents/guardians are provided with both verbal and written
information about the study and written informed consent
is obtained prior to enrolment of their child into the trial.
Subject Selection
Children satisfying the inclusion and exclusion criteria
who present to the recruiting hospital ED during the
study period are eligible for enrolment.
Definition of Disease State
The eligible participants will be patients aged 6 months to
8 years, who present with gingivostomatitis (herpetic or
non herpetic), ulcerative pharyngitis, herpangina and hand
foot and mouth disease as assessed by the treating clini-
cian, in associated with a history of poor oral fluid intake
(as assessed by parent and defined as oral fluid intake of
less than 10 ml/kg of fluid in the preceding 2 hours).
Inclusion and Exclusion Criteria
Inclusion and exclusion criteria are presented in Table
1. Exclusion criteria include hypersensitivity to any of
the contents of the study medication or similar drugs
(other amide local anaesthetics), and patients with dis-
eases (such as epilepsy impaired cardiac conduction,
bradycardia, impaired hepatic function) that may be
complicated by the study drugs.
Patient Randomisation
Patients who fulfil the eligibility criteria and whose par-
ents provide informed consent will be randomised to
either 2% viscous lidocaine or placebo.
The randomisation schedule will be computer gener-
ated using block randomisation by the Clinical Biostatis-
tics and Epidemiology Unit (CEBU, Murdoch Children’s
Research Institute, Melbourne, Australia). Random block
sizes will be used. The randomisation will not be strati-
fied. Sequentially numbered bottles of either lidocaine
or placebo will be arranged according to this schedule
by a study pharmacist. Once a patient has been rando-
mised they will be given the next available study number
which will equate to an allocation of study drug dis-
pensed in two bottles (labelled Bottle A and Bottle B).
At the time of randomisation patients will be given a
dose of study solution from Bottle A which will contain
the study drug according to their random allocation.
Bottle B will contain the alternative mixture i.e. lido-
caine if randomised to placebo and placebo if rando-
mised to lidocaine. After 60 minutes the treating
clinician may prescribe a dose from this second bottle if
clinically warranted. This ensures that all participants in
the study have access to the active treatment.
All study drugs will be packaged in blinded containers
stored in a locked cupboard labelled only with the study
details and the study number. Only the study pharma-
cist will be aware of the treatment allocation.
Randomised treatments
Study drug: 2% viscous lidocaine mixture (Xylocaine
Viscous
®, Astra Zeneca)
This is a viscous mixture of 2% lidocaine hydrochloride,
made up with methyl hydroxybenzoate, propyl hydroxy-
benzoate, sodium hydroxide, saccharin sodium, cherry
extract (water, flavour, citric acid and amaranth), car-
mellose sodium and water for injections. The dose of
2% viscous lidocaine at the RCH conforms to the local
Paediatric Pharmacopoeia at 0.15 ml/kg [28].
Placebo: contains methylcellulose and cherry flavouring
The placebo will be made up by the RCH Pharmacy
from stock ingredients. The placebo will be identical to
the study drug in terms of appearance, flavour and
smell.
For both groups
0.15 ml/kg of lidocaine/placebo will be administered
once at the time of randomisation by the treating nurse
via a measured syringe to the oral cavity of the partici-
pant ensuring coverage to inflamed mucosa and ulcera-
tive lesions. If the participant is mature enough, he/she
will be instructed to gargle and spit out the study drug/
placebo. If the participant is not mature enough to fol-
low these instructions, he/she may swallow or spit out
the study drug/placebo. It will be recorded if the lido-
caine/placebo is spat out within 1-2 seconds of adminis-
tration. Further lidocaine/placebo will not be
administered.
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viscous lidocaine may not be prescribed by the treat-
ing clinician during the 90 minute study period or for
the preceding 90 minutes due to risk of lidocaine
toxicity.
Breaking of the Study Blind
On Study
In a medical emergency, when management of a partici-
pant’s condition requires knowledge of the investiga-
tional product, the randomisation code may be broken
to determine the treatment allocation of the participant.
If this is required the investigator can contact the phar-
macy to obtain the treatment identity. If possible, such
emergencies will be discussed with the Principal Investi-
gator before disclosure of the treatment allocation (or as
soon as possible thereafter). Reasons for breaking a code
must be clearly explained and justified on the partici-
pant’s CRF. The date on which the code is broken
together with the identity of the person(s) responsible
for requesting the code to be broken will also be
documented.
Following Completion of the Study
Study unblinding will only take place once the Statistical
Analysis Plan has been agreed by the trial team and
after the final database has been locked. This will be
achieved by obtaining the schedule linking Randomisa-
tion Numbers with the administered treatment from
CEBU.
Study Procedure
Dose and administration schedule
T h es i n g l ed o s eo fs t u d yd r u gw i l lb ea d m i n i s t e r e da t
time 0 as outlined in Study Flow Chart (Figure 1). The
amount of fluid ingested within 30 and 60 minutes will
be recorded on a Fluid Balance Chart.
After the end of the 60 minute fluid trial and once the
outcome data has been collected, the treating clinician
will complete a fluid assessment on the participant. At
this point, if the treating clinician feels that a participant
has not had enough fluid, he/she may decide to:
￿ Administer the second bottle allocated to that par-
ticipant (Bottle B) - participants previously given pla-
cebo will receive the active drug (i.e. 2% viscous
lidocaine), and vice versa, and/or
￿ Administer other oral analgesia e.g. paracetamol or
ibuprofen
The study will terminate at 90 minutes (i.e. 30 min-
utes after the end of the 60 minute fluid trial for assess-
ment of adverse events) where the participant will be
reviewed for signs of aspiration. However, if at any point
during the trial the participant starts coughing and/or
show other signs of aspiration, he/she will be urgently
reviewed by the treating clinician. A completed partici-
pant is one who has had the solution administered, and
has had their fluid intake monitored for a minimum of
60 minutes from the time of administration of the study
Table 1 Inclusion and exclusion criteria
Inclusion criteria - all of:
Diagnosed by the treating doctor with ulcerative pharyngitis, herpangina, hand foot and mouth disease, herpetic gingivostomatitis OR non-herpetic
gingivostomatitis
Parental complaint of child’s poor oral intake
Intake of less than 10 ml/kg of fluid within 2 hours preceding presentation to RCH ED
Exclusion criteria - any of:
Presence of more than 2 vomits within 24 hours preceding presentation to RCH ED
Presence of active painful dental disease (caries, dental abscess) or painful recent mouth trauma, mouth burn, or post-operative state (minimum of 5
days)
Systemic toxicity related to infection, as defined by the treating doctor
Severe dehydration requiring immediate therapy, as defined by the treating doctor
Known allergy to local anaesthetic, gelatine, methylcellulose, cherry flavouring, paracetamol or ibuprofen
Chronic renal or liver impairment
History of epilepsy or cardiac disease
Presence of acute porphyria
Presence of malignancy
Current use of anti-arrhythmic drugs, xylocaine, phenytoin, cimetidine or beta-blockers, warfarin, lithium, angiotensin converting enzyme (ACE)
inhibitors, thiazide diuretics, frusemide, aspirin, salicylates, probenecid, anti-diabetic medications, zidovudine, cardiac glycosides or methotrexate
More than 1 dose of 2% viscous lignocaine or medications containing lignocaine as the active ingredient for this episode of illness
Pre-existing upper airway obstruction and/or swallowing difficulties
Analgesia taken within 1 hour preceding enrolment to study
Non-English speaking parents/guardians
RCH ED Royal Children’s Hospital emergency department
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minute study period, the reason for the premature ter-
mination will be documented on the CRF. After the
completion of the 60 minute trial of fluids routine care
will follow as directed by the treating clinician.
Complications recorded will include: allergic reactions
(including anaphylaxis), seizures, cardiac arrhythmia,
and clinical episodes of aspiration.
Outcome measures
The primary outcome is the amount of fluid ingested by
each child, expressed in ml/kg, within 60 minutes from
the time of administration of the study mixture.
The secondary outcome measures are in 2 groups
Short term
those within 60 minutes - and longer term - those
between 60 and 90 minutes. Comparisons between
groups will only be made in the short term outcomes
since both groups will have access to lidoocaine after 60
minutes.
Short term
(1) the proportion of subjects in each arm to have
ingested more than 5 ml/kg of fluid within 30 and 60
minutes from the time of administration of the study
mixture; (2) the proportion of subjects in each arm to
have ingested more than 10 ml/kg of fluid within 30
Potential patient presents at ED Triage 
Eligibility assessed and informed consent 
obtained 
Double-blinded randomization 
Placebo mixture 
(Bottle A) 
60 minute trial of fluids 
Primary outcome: fluid ingested (ml/kg) 
Treating doctor to review fluid intake with 
option to give Bottle B and/or other 
analgesia  
Clinical review/ End of trial 
30 minutes later   
Usual ED care  
2% viscous lignocaine 
(Bottle A) 
Figure 1 Study Flow Chart. The schedule of study observations that will be recorded during the 60 minute study period and the 30 minute
observation period. (legend) ED emergency department
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study mixture.
Longer term
(1) incidence of adverse events (seizures, cardiac
arrhythmias and aspiration) within the 90 minute study
period; (2) the proportion of subjects who require fluid
administration via intravenous line or nasogastric tube
(oral hydration failures); (3) the proportion of subjects
requiring hospital admission; (4) duration of stay in the
ED
Sample size, power and statistical methods
There is currently no published literature on the effec-
tiveness of 2% viscous lidocaine for improving oral fluid
intake in painful infectious mouth conditions, hence we
carried out a pilot study of 20 patients to document the
mean fluid intake and spread of the data.
The data from the pilot study found a mean difference
of 4.3 mls/kg (standard deviation = 7 mls/kg) ingested
over a 60 minute period between the two treatment
groups. Assuming a slightly conservative estimate of the
treatment effect of 4 mls/kg (standard deviation = 7),
w o u l dr e q u i r eas a m p l es i z eo f5 0c h i l d r e np e rg r o u p
(100 children in total), based on 80% power and 5% sig-
nificance. A review of expert clinical opinion (10 paedia-
tric emergency attendings in Melbourne, Australia)
concluded that a difference of 4-5 mls/kg represented a
clinically important difference.
Based on the recruitment rate in the pilot study (20
participants in 5 months) we expect patient recruitment
to take 2 years (the 20 patients from the pilot study will
be included in the final analysis). We have not allowed
f o ra n yl o s s - t o - f o l l o wu pi nt h i st i m el i n ea sw ee x p e c t
to retain all patients for the 60 minutes needed for the
study.
Analysis will be by intention to treat. Data will be ana-
lysed descriptively and statistically using the STATA
data analysis program. Data for the primary outcome
will be reported with an estimate of the difference in
means and its 95% confidence interval - obtained using
an unadjusted linear regression. Since this is an RCT,
and the outcome measure is measured on a continuous
scale, the t-test will be used to compare the 2 groups. If
necessary due to skewed data, the data will be log-trans-
formed. Secondary outcomes in the short term group
will be analysed with t-tests for continuous data and
chi-squared tests for categorical data, while the longer
term group will have descriptive statistics only. As a
sensitivity analysis, all treatment comparisons for pri-
mary and secondary outcomes will also be presented
adjusted for age at presentation to account for any
chance imbalance between the treatment groups with
respect to this potentially confounding factor using
linear and logistic regression models for continuous and
binary outcomes respectively.
Adverse experiences
All adverse experiences either observed by the investiga-
tor or one of the clinical staff, or reported by the
patient’s parents/guardians spontaneously or in response
to a direct question, that occur during the 60 minute
study period, and the 30 minute observation period, will
be evaluated by the investigator and noted in the
a d v e r s ee x p e r i e n c es e c t i o no ft h ep a t i e n t ’sC R F .E v e n t s
after the study period also thought to be due to a study
intervention will be included.
Serious adverse events
A serious adverse event (SAE) is generally defined as
any event that is fatal, life-threatening, permanently dis-
abling, incapacitating or results in hospitalisation, pro-
longs a hospital stay or is associated with congenital
abnormality, carcinoma or overdose. SAEs will be
judged as to how likely they are to be related to the
study drug; this judgement is to be made by the partici-
pant’s treating clinician. These may include conditions
such as pulmonary aspiration, seizures and cardiac
arrhythmia.
Reporting SAEs
SAEs need to be reported within 24 hrs by telephone to
the principal investigator. The SAE will be reported to
the ethics committee within 48 hours. SAEs will also be
reported to the consultant of the child’s treating team.
The medical consultant will initiate appropriate manage-
ment and inform the family if the family is not already
aware of the event. This reporting is the responsibility
of the principal investigator. All SAEs will be followed
by the study investigator until resolution.
Limitations
This trial has some potential limitations. While the
study endeavours to capture all patients presenting
with painful infectious mouth conditions, patients will
only be approached if researchers are available in the
ED. In addition, some patients will mistakenly receive
oral analgesia by triage nursing staff at the triage desk
or while waiting to be seen even though research staff
are available and therefore become ineligible for
enrolment.
Time plan
Recruitment has begun in early 2011 for the 80 remain-
ing patients needed for the study. It is anticipated
patient recruitment will be completed by the end of
2013.
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